AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Venus Concept (VERO) has received FDA clearance for its Venus NOVA platform, a non-invasive treatment device for body, face, and skin. Despite innovative product developments, the company faces financial challenges, including negative profitability and high debt levels. Revenue growth has declined 32.5% over the past three years, and the company has a negative EPS of -50.78 and a net margin of -68.77%. The Altman Z-Score of -8.22 indicates a high risk of bankruptcy.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet